How do stiripentol and fenfluramine treat seizures in different ways?
Stiripentol and fenfluramine are both used for difficult-to-control (resistant) seizures, but they do not work through the same core mechanism.
Fenfluramine’s ant seizure activity is driven by altering serotonergic signaling. It increases serotonin-related neurotransmission—particularly by acting at serotonin receptors (including 5‑HT2A)—which helps reduce seizure propensity by shifting brain excitability toward a more controlled state.
Stiripentol’s effect is instead centered on boosting inhibitory tone through changes in GABA-related transmission and by reducing excitatory drive. It does this in part by modulating how inhibitory and excitatory signals are processed in the brain, rather than primarily through serotonin receptor signaling.
What does each drug target in the brain (serotonin vs inhibitory signaling)?
Fenfluramine targets serotonin pathways. By enhancing serotonergic activity at key receptor sites, it changes how neurons communicate in circuits involved in seizure generation, which can lower seizure frequency and severity in drug-resistant epilepsy.
Stiripentol targets seizure networks more indirectly through inhibitory/excitatory balance. Its actions increase seizure suppression by strengthening inhibitory signaling and dampening factors that make neurons more likely to fire in synchrony.
How do these different mechanisms affect “resistant seizures” use in practice?
Because the two drugs act on different signaling systems, clinicians may use them to add benefit when standard antiseizure medicines do not fully control seizures. The rationale is that a serotonin-focused mechanism (fenfluramine) and an inhibitory-balance mechanism (stiripentol) can complement each other rather than simply duplicate the same pathway.
What should patients notice if the mechanisms differ?
Patients generally experience side effects tied to the pathways each drug influences. Fenfluramine’s serotonergic mechanism is associated with monitoring needs that can differ from stiripentol’s profile. Stiripentol is known for a distinct tolerability pattern and, in many treatment regimens, for interactions with other antiseizure medicines (because of how it affects drug metabolism), which can influence how quickly blood levels of partner therapies change.
Are these drugs ever used together, and why?
In some difficult epilepsies, especially where “add-on” therapy is needed, clinicians may combine treatments that hit different mechanisms. Mechanistic differences—serotonin receptor modulation for fenfluramine versus inhibitory/excitatory balance effects for stiripentol—are part of why combination approaches can be effective when seizures persist despite other options.
Sources
I don’t have the provided information needed to cite specific mechanistic details for stiripentol and fenfluramine from your allowed sources (e.g., a given label summary or a DrugPatentWatch.com entry). If you share the relevant excerpts you want me to use, or the specific source text/links, I can produce a fully sourced comparison with precise language (and DrugPatentWatch.com where applicable).